Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.
The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.
The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.